News Release

BAXTER AND MILTENYI BIOTEC SIGN 5-YEAR DISTRIBUTION AGREEMENT FOR CELLULAR THERAPY PRODUCTS

DEERFIELD, Illinois and COLOGNE, Germany, September 24, 2003 - Baxter Healthcare Corporation and Miltenyi Biotec GmbH announced today that they have signed an agreement whereby Miltenyi Biotec will have exclusive rights for five years to distribute, market and sell Baxter's cellular therapy products worldwide, with the exception of China, Japan, Korea and Taiwan. Baxter will continue to manufacture these products.

Baxter's cellular therapy products included in the agreement are the Isolex 300i Magnetic Cell Selection System v2.5, the Cytomate Cell Processing System, as well as preservation and expansion bags used for cryopreservation and cell cultures and biologic reagents.

"We believe that this distribution agreement with Miltenyi is the best way to keep cell selection, preservation and expansion products broadly available to customers worldwide," said Jim Utts, general manager of Baxter Oncology. "Miltenyi Biotec's dedicated focus on cellular therapies and their global sales force will ensure that our customers' needs are met."

"We are very pleased with the agreement we have signed with Baxter," said Stefan Miltenyi, managing director for Miltenyi Biotec. "Not only do these products represent a significant enhancement to our current portfolio, we also gain immediate access to the United States, one of the key growth markets for us. We plan on leveraging our existing distribution infrastructure to continue to provide customers with the quality products and services they require."

ABOUT BAXTER
 
Baxter Healthcare Corporation is the principal domestic operating subsidiary of Baxter International Inc. (NYSE: BAX). Baxter International Inc., through its subsidiaries, assists health- care professionals and their patients with treatment of complex medical conditions, including cancer, hemophilia, immune disorders, kidney disease and trauma. The company applies its expertise in medical devices, pharmaceuticals and biotechnology to make a meaningful difference in patients' lives.

ABOUT MILTENYI BIOTEC

Miltenyi Biotec GmbH is a diversified biotechnology company focused on cell separation, molecular biology, GMP manufacturing and cellular therapies. By combining competencies in biologics and device technologies, Miltenyi Biotec is uniquely positioned to provide researchers and clinicians with a wide range of advanced solutions for cellular research, cell therapies and blood/plasma treatments. Additional information can be accessed via the web at www.miltenyibiotec.com

Isolex and Cytomate are registered trademarks of Baxter International Inc. and its affiliates.

FOR ADDITIONAL INFORMATION: